Cargando…
Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of high...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279419/ https://www.ncbi.nlm.nih.gov/pubmed/32438758 http://dx.doi.org/10.3390/ijms21103594 |
_version_ | 1783543557395578880 |
---|---|
author | Fernández-Martínez, Juan Luis Álvarez-Machancoses, Óscar deAndrés-Galiana, Enrique J. Bea, Guillermina Kloczkowski, Andrzej |
author_facet | Fernández-Martínez, Juan Luis Álvarez-Machancoses, Óscar deAndrés-Galiana, Enrique J. Bea, Guillermina Kloczkowski, Andrzej |
author_sort | Fernández-Martínez, Juan Luis |
collection | PubMed |
description | We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of highly underdetermined phenotype prediction problem, by looking for the minimum-scale signatures (header genes) corresponding to different random holdouts. The biological pathways can be identified performing posterior analysis of these signatures established via cross-validation holdouts and plugging the set of most frequently sampled genes into different ontological platforms. That way, the effect of helper genes, whose presence might be due to the high degree of under determinacy of these experiments and data noise, is reduced. Our results suggest that common pathways for Alzheimer’s disease and MCI are mainly related to viral mRNA translation, influenza viral RNA transcription and replication, gene expression, mitochondrial translation, and metabolism, with these results being highly consistent regardless of the comparative methods. The cross-validated predictive accuracies achieved for the LOAD and MCI discriminations were 84% and 81.5%, respectively. The difference between LOAD and MCI could not be clearly established (74% accuracy). The most discriminatory genes of the LOAD-MCI discrimination are associated with proteasome mediated degradation and G-protein signaling. Based on these findings we have also performed drug repositioning using Dr. Insight package, proposing the following different typologies of drugs: isoquinoline alkaloids, antitumor antibiotics, phosphoinositide 3-kinase PI3K, autophagy inhibitors, antagonists of the muscarinic acetylcholine receptor and histone deacetylase inhibitors. We believe that the potential clinical relevance of these findings should be further investigated and confirmed with other independent studies. |
format | Online Article Text |
id | pubmed-7279419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72794192020-06-17 Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning Fernández-Martínez, Juan Luis Álvarez-Machancoses, Óscar deAndrés-Galiana, Enrique J. Bea, Guillermina Kloczkowski, Andrzej Int J Mol Sci Article We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of highly underdetermined phenotype prediction problem, by looking for the minimum-scale signatures (header genes) corresponding to different random holdouts. The biological pathways can be identified performing posterior analysis of these signatures established via cross-validation holdouts and plugging the set of most frequently sampled genes into different ontological platforms. That way, the effect of helper genes, whose presence might be due to the high degree of under determinacy of these experiments and data noise, is reduced. Our results suggest that common pathways for Alzheimer’s disease and MCI are mainly related to viral mRNA translation, influenza viral RNA transcription and replication, gene expression, mitochondrial translation, and metabolism, with these results being highly consistent regardless of the comparative methods. The cross-validated predictive accuracies achieved for the LOAD and MCI discriminations were 84% and 81.5%, respectively. The difference between LOAD and MCI could not be clearly established (74% accuracy). The most discriminatory genes of the LOAD-MCI discrimination are associated with proteasome mediated degradation and G-protein signaling. Based on these findings we have also performed drug repositioning using Dr. Insight package, proposing the following different typologies of drugs: isoquinoline alkaloids, antitumor antibiotics, phosphoinositide 3-kinase PI3K, autophagy inhibitors, antagonists of the muscarinic acetylcholine receptor and histone deacetylase inhibitors. We believe that the potential clinical relevance of these findings should be further investigated and confirmed with other independent studies. MDPI 2020-05-19 /pmc/articles/PMC7279419/ /pubmed/32438758 http://dx.doi.org/10.3390/ijms21103594 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fernández-Martínez, Juan Luis Álvarez-Machancoses, Óscar deAndrés-Galiana, Enrique J. Bea, Guillermina Kloczkowski, Andrzej Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title | Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title_full | Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title_fullStr | Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title_full_unstemmed | Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title_short | Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning |
title_sort | robust sampling of defective pathways in alzheimer’s disease. implications in drug repositioning |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279419/ https://www.ncbi.nlm.nih.gov/pubmed/32438758 http://dx.doi.org/10.3390/ijms21103594 |
work_keys_str_mv | AT fernandezmartinezjuanluis robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning AT alvarezmachancosesoscar robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning AT deandresgalianaenriquej robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning AT beaguillermina robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning AT kloczkowskiandrzej robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning |